Home › Funds › Propel Bio Management, LLC › AQST

Propel Bio Management, LLC position in AQST

AQUESTIVE THERAPEUTICS INC · Health Care

Propel Bio Management, LLC reported holding 278,723 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$8.6M, representing 4.56% of its reported portfolio and ranking #6 among its reported holdings. Propel Bio Management, LLC has disclosed AQST holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)278.72K sh
Reported value held$8.61M
Portfolio Weight4.56%
First reportedQ1 2026
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Propel Bio Management, LLC's AQST position evolved

Propel Bio Management, LLC first disclosed a stake in AQST in Q1 2026 at 710,988 shares (US$3.0M). The position peaked in Q3 2026 at 278,723 shares, worth US$8.6M. Across 3 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 278,723 shares valued at US$8.6M — a reduction of -1,163,674 shares quarter over quarter.. Notable position changes include a 103% increase in Q2 2026 (shares rose 11% over the following quarter), a 81% trim in Q3 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 710.99K $2.95M New
Q2 2026 1.44M $6.00M Add
Q3 2026 278.72K $8.61M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AQST and 13F data

AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$45.4M), Samsara BioCapital, LLC (US$10.4M), Blue Owl Capital Holdings LP (US$6.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AQST

All AQST fund holders →

FAQ

How long has Propel Bio Management, LLC held AQST?

Propel Bio Management, LLC has disclosed AQST holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Propel Bio Management, LLC's current position in AQST?

As of Q3 2026, Propel Bio Management, LLC holds 278.72K shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $8.61M, representing 4.56% of its reported portfolio and ranking #6.

Has Propel Bio Management, LLC been buying or selling AQST?

In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in AQST. The position peaked in Q3 2026 at 278.72K shares.

Which other funds hold AQST?

Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Blue Owl Capital Holdings LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.